Specifically, the new class of anti-HER2 agents represented by antibody drug conjugates (ADCs) have shown to bind HER2, to enter the cell, and to leave their membrane-permeable topoisomerase I inhibitor payload causing a catastrophic DNA damage in both the targeted and neighboring tumor cells (Ponde et al., 2019). This evidence concerns the gene ERBB2 and neoplasm.